Latigo Biotherapeutics (NASDAQ:LTGO) Upgraded by Guggenheim to Strong-Buy Rating

Latigo Biotherapeutics (NASDAQ:LTGO) was upgraded by equities researchers at Guggenheim to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

LTGO has been the topic of a number of other research reports. Wall Street Zen raised shares of Latigo Biotherapeutics to a “hold” rating in a report on Saturday, August 15th. The Goldman Sachs Group initiated coverage on Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $73.00 price target on the stock. Leerink Partners initiated coverage on Latigo Biotherapeutics in a report on Tuesday. They issued an “outperform” rating and a $36.00 price target on the stock. Finally, Jefferies Financial Group began coverage on Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 price objective for the company. Four investment analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Strong Buy” and an average target price of $52.25.

Latigo Biotherapeutics Trading Up 1.1%

NASDAQ LTGO opened at $22.26 on Tuesday. Latigo Biotherapeutics has a one year low of $17.22 and a one year high of $25.93.

Insider Transactions at Latigo Biotherapeutics

In related news, Director James B. Tananbaum purchased 140,000 shares of Latigo Biotherapeutics stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the purchase, the director owned 2,008,024 shares in the company, valued at approximately $36,144,432. The trade was a 7.49% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Foresite Capital Management V, purchased 140,000 shares of Latigo Biotherapeutics stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. This trade represents a 7.49% increase in their position. The disclosure for this purchase is available in the SEC filing.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.